Taysha Gene Therapies, Inc. Capital Expenditures
Taysha Gene Therapies, Inc. (TSHA) reported Capital Expenditures of $23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was -$1.00K, a 150.00% decline year-over-year.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $24.00K, a 93.65% decline year-over-year.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $250.00K.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $108.00K, a 208.57% increase year-over-year.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $738.00K, a 97.33% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $374.00K, a 90.33% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.87M, a 81.24% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $20.62M, a 34.73% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 0 month | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $23.00K 10-Q · filed 2026-08-11 | $273.00K derived: sum of 3 quarters · filed 2026-08-11 | $381.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $24.00K 10-Q · filed 2026-05-06 | $274.00K derived: sum of 2 quarters · filed 2026-05-06 | $382.00K derived: sum of 3 quarters · filed 2026-05-06 | $384.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $358.00K derived: sum of 2 quarters · filed 2026-03-19 | $360.00K derived: sum of 3 quarters · filed 2026-08-11 | $738.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $110.00K derived: sum of 2 quarters · filed 2026-08-11 | $488.00K 10-Q · filed 2025-11-04 | $486.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $380.00K 10-Q · filed 2026-08-11 | $378.00K derived: sum of 3 quarters · filed 2026-08-11 | $413.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $378.00K 10-Q · filed 2026-05-06 | $376.00K derived: sum of 2 quarters · filed 2026-05-06 | $411.00K derived: sum of 3 quarters · filed 2026-05-06 | $612.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $33.00K derived: sum of 2 quarters · filed 2026-03-19 | $234.00K derived: sum of 3 quarters · filed 2026-03-19 | $374.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $236.00K derived: sum of 2 quarters · filed 2025-11-04 | $376.00K 10-Q · filed 2025-11-04 | $393.00K derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $341.00K 10-Q · filed 2025-08-12 | $358.00K derived: sum of 3 quarters · filed 2025-08-12 | $358.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $140.00K 10-Q · filed 2024-05-14 | $157.00K derived: sum of 2 quarters · filed 2025-02-26 | $157.00K derived: sum of 3 quarters · filed 2025-02-26 | $109.00K derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $17.00K derived: sum of 2 quarters · filed 2025-02-26 | -$31.00K derived: sum of 3 quarters · filed 2025-02-26 | $3.87M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$48.00K derived: sum of 2 quarters · filed 2024-11-13 | $3.85M 10-Q · filed 2024-11-13 | $6.16M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $3.85M 10-Q · filed 2024-08-12 | $6.16M derived: sum of 3 quarters · filed 2024-08-12 | $8.18M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $3.90M 10-Q · filed 2024-05-14 | $6.21M derived: sum of 2 quarters · filed 2024-05-14 | $8.23M derived: sum of 3 quarters · filed 2024-05-14 | $16.09M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.33M derived: sum of 2 quarters · filed 2024-03-19 | $12.19M derived: sum of 3 quarters · filed 2024-03-19 | $20.62M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $9.88M derived: sum of 2 quarters · filed 2023-11-14 | $18.31M 10-Q · filed 2023-11-14 | $26.58M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $7.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $16.29M 10-Q · filed 2023-08-14 | $24.56M derived: sum of 3 quarters · filed 2023-08-14 | $28.06M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $8.43M 10-Q · filed 2023-05-11 | $16.70M derived: sum of 2 quarters · filed 2023-05-11 | $20.20M derived: sum of 3 quarters · filed 2023-05-11 | $23.20M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $11.77M derived: sum of 2 quarters · filed 2023-03-28 | $14.77M derived: sum of 3 quarters · filed 2023-03-28 | $15.30M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.50M derived: sum of 2 quarters · filed 2022-11-08 | $7.03M 10-Q · filed 2022-11-08 | $7.08M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.53M 10-Q · filed 2022-08-11 | $3.58M derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $534.00K 10-Q · filed 2022-05-16 | $585.00K derived: sum of 2 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $82.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $31.00K 10-Q · filed 2021-11-10 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |